Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus SANCTURA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus SANCTURA XR.
ANTRENYL vs SANCTURA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Category C
Category C
Anticholinergic
Anticholinergic